Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence

Bobin‐Dubigeon, Christine; Lefrancois, Armelle; Classe, Jean‐Marc; Joalland, Marie-Pierre; Bard, Jean‐Marie

doi:10.1016/j.clinbiochem.2015.07.020

Cited by 16 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we did not evaluate the mechanism for the increase in PON1 activity in our study, it has been shown that simvastatin can modulate gene expression of this enzyme [50]. Recent studies report a decrease in serum PON1 activity in breast cancer patients [51,52], and it has been suggested that serum PON1 concentration could be an efficient prognostic biomarker for the success of radiotherapy in patients with breast cancer [53]; therefore, it seems that the ability of simvastatin in increasing PON1 activity may help in its therapeutic effect on chemicalinduced breast cancer, as observed in our study.…”

Section: Discussionmentioning

confidence: 79%

Therapeutic effect of simvastatin on DMBA‐induced breast cancer in mice

Karimi

Ashrafi

Shomali

et al. 2018

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Preclinical studies have shown positive effects of statins against specific cancers. This study aimed to determine the therapeutic effect of simvastatin in 12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer. Female albino mice were divided into two groups, with or without DMBA administration. After tumor appearance, DMBA-treated group was further divided into four groups (D1-D4) as control (D1), treated with simvastatin at 80 and 40 mg/kg/day, orally (D2 and D3) and tamoxifen (50 mg/kg/day, orally) treated group (D4). After 4 weeks, animals were sacrificed, serum samples were collected and tumors were dissected for histopathological study and determination of selected parameters. The tumor marker carcinoma antigen 15-3 (CA15-3), oxidative stress parameters and prostaglandin E2 (PGE2) levels were analyzed in serum and tumors in experimental groups. Tamoxifen and high dose of simvastatin improved parameters of mammary carcinogenesis including mean tumor volume, body weight and percent of mortality as compared to mice with breast tumors without treatment (D1). Additionally, simvastatin usage increased total antioxidant capacity (TAC) level, paraoxonase 1 (PON1) activity in serum and decreased total oxidant status (TOS) and malondialdehyde (MDA) levels in tumors similar to tamoxifen. No significant decrease was found in serum CA 15-3 and tumor PGE2 levels in simvastatin and tamoxifen treated groups as compared to D1 group. These data suggest that simvastatin has anticancer effects which are relatively similar to that of tamoxifen in an animal model of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 79%

Therapeutic effect of simvastatin on DMBA‐induced breast cancer in mice

Karimi

Ashrafi

Shomali

et al. 2018

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…For example, decreased serum PON1 activity and increased levels of lipid peroxidation have been reported in 45 Pakistani patients with oral squamous cell carcinoma [ 29 ], and 30 Turkish patients with esophageal squamous cell carcinoma [ 30 ], and a further 25 Turkish patients with papillary thyroid cancer [ 31 ]. The activity of PON1 enzyme was shown to be low in 50 Egyptian patients with colorectal cancer but with significant increases one month post-surgery [ 32 ]; similar to 49 French patients with BC recurrence [ 33 ]. This latter study also showed an inverse relationship between serum PON1 activity and serum amyloid A concentrations.…”

Section: Discussionmentioning

confidence: 99%

“…it is in linkage disequilibrium with the PON1 -108 promoter polymorphism; the mutation which is more clearly responsible for the observed changes [ 7 ]. Recent studies reported a decrease in serum PON1 activity in BC patients [ 2 , 10 ]. In addition, the M allele of the L55M polymorphism was associated with a higher incidence of BC [ 11 – 13 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients

et al. 2017

View full text Add to dashboard Cite

Paraoxonase-1 (PON1) is an intra-cellular antioxidant enzyme found also in the circulation associated with high-density lipoproteins. The activity of this enzyme has been shown to be decreased in breast cancer (BC) patients. The aims of our study were to investigate the changes produced by radiotherapy (RT) on activity and concentration of serum PON1 in BC patients, and to evaluate the observed variations in relation to clinical and pathological characteristics of patients and tumors, and the response to treatment. We studied 200 women with BC who were scheduled to receive RT following excision of the tumor. Blood for analyses was obtained before and after the irradiation procedure. The control group was composed of 200 healthy women. Relative to control, BC patients had significantly lower serum PON1 activities pre-RT, while PON1 concentrations were at similar levels. RT was associated with a significant increase in serum PON1 activities and concentrations. We observed significant differences in serum PON1 concentrations post-RT between patients with luminal A or luminal B tumors. Serum PON1 concentration post-RT was markedly lower in BC patients with metastases. We conclude that benefit from RT accrues to the BC patients not only through its direct effect on cancer cells but also indirectly by improving the organism’s anti-oxidant defense mechanisms. In addition, our preliminary evidence suggests that the measurement of serum PON1 concentration post-RT could be an efficient prognostic biomarker, and may be used as an index of the efficacy of the RT.

show abstract

“…In regard to the methylation of PON1 , hypomethylated CpGs in the promoter of PON1 was predicted to be an underlying risk of bleeding after dual antiplatelet therapy . Moreover, recent investigations indicated that PON1 had considerable effect on molecular disorders connected with cancer . Some researchers found that measurement of serum PON1 concentration post‐radiotherapy could be an efficient prognostic biomarker and an index of the efficacy of the radiotherapy .…”

Section: Introductionmentioning

confidence: 99%

“…16 Moreover, recent investigations indicated that PON1 had considerable effect on molecular disorders connected with cancer. [17][18][19] Some researchers found that measurement of serum PON1 concentration post-radiotherapy could be an efficient prognostic biomarker and an index of the efficacy of the radiotherapy. 20 And in this paper, we devoted to explaining the mechanism of PON1 in KIRP.…”

mentioning

confidence: 99%

PON1 hypermethylation is associated with progression of renal cell carcinoma

2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

In this study, our aim was to exploring the influences of DNA methylation of PON1 on cell proliferation, migration and apoptosis of renal cancer cells. The genome‐wide methylation array of renal cell carcinoma samples and adjacent tissues were obtained from the cancer genome atlas (TCGA) database. By analysing the DNA methylation and conducting the CpG islands array, methylation status expressed in renal tumour samples and normal renal tissue samples were detected. Methylation‐specific PCR (MS‐PCR) and qRT‐PCR were employed to detect the methylation level and mRNA expression of PON1. Wound‐healing assay, transwell assay and MTT assay were utilized to detecting the migration, invasion and proliferation abilities, respectively. The cell apoptosis was testified by Tunnel assay. In addition, the effect of PON1 on renal cancer cells was verified by experiments in vivo. The methylation status of different genes in renal cell carcinoma samples was obtained by CpG islands arrays and hypermethylated PON1 was selected for further study. PON1 was down‐regulated in renal cell carcinoma tissues detected by qRT‐PCR and Western blot. Both in vitro and vivo experiments indicated that the sunitinib‐resistant in renal cancer cells could be suppressed by treat with 5‐Aza‐dC or TSA, and the effect came out more obvious after 5‐Aza‐dC and TSA co‐treatment. In detail, the demethylation of PON1 inhibited the migration, invasion and proliferation of renal cancer cells and also arrested more cells in G0/G1 phase. The vivo experiment indicated that demethylated PON1 suppressed the growth of tumour. Hypermethylated PON1 promoted migration, invasion and proliferation of sunitinib‐resistance renal cancer cells and arrested more cells in G0/G1 phase.

show abstract

Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence

Cited by 16 publications

References 13 publications

Therapeutic effect of simvastatin on DMBA‐induced breast cancer in mice

Therapeutic effect of simvastatin on DMBA‐induced breast cancer in mice

Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients

PON1 hypermethylation is associated with progression of renal cell carcinoma

Contact Info

Product

Resources

About